Navigation Links
First Human Study to Show 'Sun Chlorella A' Supports Heart Health
Date:3/30/2009

RICHMOND, Va., March 30 /PRNewswire/ -- A new study, published in the Journal of Medicinal Food, showed that consumption of as little as 8 grams (1/3 ounce) of "Sun Chlorella A" daily resulted in noticeable reductions in body fat percentage, serum total cholesterol, and fasting blood glucose levels.

For a 12-week period, 34 participants ingested four grams of "Sun Chlorella A" tablets each morning and evening. Seventeen subjects were healthy; the other 17 were at high risk for developing lifestyle-related illnesses.

Both groups had a decrease in body fat percentage and total serum cholesterol. However, the high-risk group also experienced lowered blood glucose, possibly due to improved insulin sensitivity induced by adding Chlorella to the daily diet.

Heart disease and stroke are the number one and three causes of death for both men and women in the U.S. Risk factors include elevated serum cholesterol, high blood pressure, a sedentary lifestyle, unhealthy diet, smoking, obesity, and hyperglycemia.

According to Mark Drucker, M.D., "Heart health is important to everyone. Remember, our hearts must be nourished to stay healthy. With protein, minerals, vitamins and fiber, Sun Chlorella is what I take, and what I recommend to all my patients."

Chlorella is a single-cell, fresh water green alga. Past research has shown that Chlorella is effective for immune activation, growth promotion, and detoxification of heavy metals and pesticides. However, unlike this recent study, most of the prior research used laboratory animals.

Dr. Randall E. Merchant earned his Doctoral and Master of Sciences degrees from the University of North Dakota. Dr. Merchant is a Professor of Anatomy and Neurosurgery at Virginia Commonwealth University, and has conducted several clinical investigations on the role of nutrition on overcoming the effects of certain chronic illnesses.

References

Toru Mizoguchi, Isao Takehara, Tohru Masuzawa, Toshiro Saito, and Yo Naoki, "Nutrigenomic Studies of Effects of Chlorella on Subjects with High-Risk Factors for Lifestyle-Related Diseases", JOURNAL OF MEDICINAL FOOD, J Med Food 11 (3) 2008, 395-404

Janet Poveromo, Aiming for the Heart to Target Cardiovascular Health Specifically Ingredient Companies are Broadening their Scope of What's Beneficial, niemagazine.com, October 2008


'/>"/>
SOURCE Randall E. Merchant, Ph.D.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... 2017 The Global Effective Microorganisms (EM) ... report has covered and analysed the potential of Global Effective ... size, shares and growth factors. The report identifies and analyses ... in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, spread ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign ... for the Access to Contraception for Women Servicemembers and Dependents Act of 2017. ... (D-CA), will help to ensure that all members of the Armed Forces receive ...
(Date:4/28/2017)... ... , ... It's not always common knowledge whether or not a certain sickness ... to whether or not they are contagious, and most people don't know the answer ... took a look into the matter. , They discovered that the main reason ...
(Date:4/28/2017)... UT (PRWEB) , ... April 28, 2017 , ... Beginning ... some of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ... be changing the formula in the following ways:, , Removal ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it ... 19 hours without sleep can compromise motor reaction time, which can increase the risk of ... is sharing the following tips from the NSF to help you sleep better and feel ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: April ... “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on her ... Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she was ...
Breaking Medicine News(10 mins):